Congress Wealth Management LLC DE Sells 898 Shares of Repligen Co. (NASDAQ:RGEN)

Congress Wealth Management LLC DE lowered its stake in Repligen Co. (NASDAQ:RGEN) by 5.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,835 shares of the biotechnology company’s stock after selling 898 shares during the period. Congress Wealth Management LLC DE’s holdings in Repligen were worth $2,279,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in RGEN. UMB Bank n.a. raised its stake in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Repligen in the fourth quarter worth $216,000. Worldquant Millennium Advisors LLC grew its stake in Repligen by 11.9% in the third quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company’s stock worth $7,482,000 after purchasing an additional 5,337 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Repligen by 1.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company’s stock valued at $54,078,000 after buying an additional 5,478 shares in the last quarter. Finally, Van ECK Associates Corp grew its position in shares of Repligen by 7.8% in the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock worth $6,078,000 after buying an additional 3,066 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of RGEN opened at $139.43 on Thursday. The firm has a market cap of $7.83 billion, a PE ratio of -273.39, a P/E/G ratio of 4.54 and a beta of 0.95. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $187.25. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a fifty day simple moving average of $155.26 and a two-hundred day simple moving average of $148.30.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on RGEN. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Royal Bank of Canada lifted their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Repligen presently has a consensus rating of “Hold” and a consensus price target of $178.64.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.